When oral medicines for Chronic Myeloid Leukemia (CML) first became available, they dramatically changed what it meant to live with the disease. What was once life-threatening became a condition patients could manage long-term. Survival, once the only goal, was suddenly within reach for most.

But two decades later, a new question has emerged: is survival enough? Increasingly, the answer is no. Patients and doctors are shifting the conversation from “how long can I live?” to “how well can I live?”

The Indian Context: Younger Patients, Bigger Expectations

In India, the CML story takes on unique dimensions. Patients are often diagnosed between the ages of 35 and 40—much younger than in the West. At this stage of life, people are in the middle of careers, family responsibilities, and person

See Full Page